Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
Eterna Therapeutics (Nasdaq: ERNA) has announced a stock repurchase program of up to $1 million of its outstanding common stock. The Board of Directors-authorized program allows repurchases through open market transactions, privately negotiated transactions, or other means in compliance with securities laws. The company's management will determine the timing and amount of repurchases based on market conditions, stock price, and other factors. The program has no set expiration date and can be suspended, modified, or discontinued at any time.
Eterna Therapeutics (Nasdaq: ERNA) ha annunciato un programma di riacquisto di azioni per un massimo di 1 milione di dollari delle sue azioni ordinarie in circolazione. Il programma autorizzato dal Consiglio di Amministrazione consente i riacquisti tramite transazioni sul mercato aperto, transazioni negoziate privatamente o altri mezzi conformi alle leggi sui titoli. La direzione dell'azienda determinerà il momento e l'importo dei riacquisti in base alle condizioni di mercato, al prezzo delle azioni e ad altri fattori. Il programma non ha una data di scadenza fissa e può essere sospeso, modificato o interrotto in qualsiasi momento.
Eterna Therapeutics (Nasdaq: ERNA) ha anunciado un programa de recompra de acciones de hasta 1 millón de dólares de sus acciones ordinarias en circulación. El programa autorizado por la Junta Directiva permite recompra a través de transacciones en el mercado abierto, transacciones negociadas privadamente u otros medios en cumplimiento con las leyes de valores. La dirección de la empresa determinará el momento y la cantidad de las recompras según las condiciones del mercado, el precio de las acciones y otros factores. El programa no tiene fecha de expiración establecida y puede ser suspendido, modificado o interrumpido en cualquier momento.
이터나 테라퓨틱스 (Nasdaq: ERNA)는 최대 100만 달러 상당의 유통 중인 보통주를 재구매하는 프로그램을 발표했습니다. 이사회에서 승인한 프로그램은 공개 시장 거래, 비공식 거래 또는 증권법을 준수하는 기타 수단을 통해 재구매를 허용합니다. 회사의 경영진은 시장 상황, 주가 및 기타 요인에 따라 재구매의 시기와 양을 결정합니다. 이 프로그램은 고정 만료일이 없으며 언제든지 중단, 수정 또는 중지될 수 있습니다.
Eterna Therapeutics (Nasdaq: ERNA) a annoncé un programme de rachat d'actions d'un montant pouvant atteindre 1 million de dollars pour ses actions ordinaires en circulation. Le programme autorisé par le Conseil d'Administration permet des rachats par le biais de transactions sur le marché libre, de transactions négociées de manière privée ou par d'autres moyens conformes aux lois sur les valeurs mobilières. La direction de l'entreprise déterminera le moment et le montant des rachats en fonction des conditions du marché, du prix des actions et d'autres facteurs. Le programme n'a pas de date d'expiration fixe et peut être suspendu, modifié ou interrompu à tout moment.
Eterna Therapeutics (Nasdaq: ERNA) hat ein Aktienrückkaufprogramm von bis zu 1 Million Dollar für ihre ausstehenden Stammaktien angekündigt. Das vom Vorstand genehmigte Programm erlaubt Rückkäufe über Transaktionen am offenen Markt, privat ausgehandelte Transaktionen oder andere Mittel, die den Wertpapiergesetzen entsprechen. Das Management des Unternehmens wird den Zeitpunkt und die Höhe der Rückkäufe basierend auf den Marktbedingungen, dem Aktienkurs und anderen Faktoren bestimmen. Das Programm hat kein festes Ablaufdatum und kann jederzeit ausgesetzt, geändert oder eingestellt werden.
- Board authorization of $1 million stock buyback program indicates confidence in company's value
- Flexible repurchase program with no set expiration date allows strategic timing of purchases
- Program demonstrates commitment to enhancing shareholder value
- Relatively small buyback amount of $1 million may have impact on share price
- Program implementation depends on market conditions and may not be fully executed
Insights
CAMBRIDGE, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics, Inc. (Nasdaq: ERNA), a leader in cell therapies, today announced that its Board of Directors has authorized a stock repurchase program of up to
Under the stock repurchase program, the repurchases may be made by the Company from time to time through open market transactions, privately negotiated transactions, or other means in accordance with applicable securities laws. The timing and amount of repurchases will be determined by the company’s management, taking into consideration market conditions, stock price, and other factors. The program does not have a set expiration date and may be suspended, modified or discontinued at any time without prior notice.
“This buyback program underscores our belief in Eterna Therapeutics’ trajectory,” says Sanjeev Luther, President and CEO. For more information, please visit https://www.eternatx.com/.
About Eterna Therapeutics Inc.
Eterna Therapeutics is a publicly traded, preclinical-stage company focused on using cutting-edge tools to deliver highly innovative, effective, and safe off-the-shelf cell therapies for the treatment of advanced solid tumors, with an initial emphasis on triple-negative breast cancer (TNBC) and platinum-resistant, TP53-mutant ovarian cancer. The company is currently focused on advancing its lead product ERNA-101, an induced allogenic mesenchymal stem cell (“iMSC”) product, designed to selectively deliver the pro-inflammatory cytokines IL-7 and IL-15 to the tumor microenvironment (TME) in order to drive significant anti-tumor immunity. ERNA-101 is built on the company's in-licensed core technology, which utilizes a best-in-class approach to engineer allogenic iPSCs to express genes of interest and to efficiently differentiate these cells into iMSCs. For more information, please visit https://www.eternatx.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Eterna's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to if and when the Company will repurchase the stock authorized by its Board and the impact of the buyback program to the Company and its shareholders. Forward-looking statements are based upon Eterna's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Eterna's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Eterna does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Investor Relations Contact:
investors@eternatx.com
FAQ
How much is Eterna Therapeutics (ERNA) stock buyback program worth?
When does Eterna Therapeutics (ERNA) stock buyback program expire?